RECRUITINGOBSERVATIONAL
Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF
Canadian Observational Study Evaluating the Long-term IMPACT of CFTR (Can-IMPACT CF)
About This Trial
This observational study intends to investigate health trends and data in cystic fibrosis patients all across Canada that are receiving modulator treatment so researchers can determine if CFTR treatments are effective over a long period of time and if so, which treatments work best for each individual. The study will collect clinical data from routine standard of care, patient reported outcomes via survey data and samples for a biobank.
Who May Be Eligible (Plain English)
Who May Qualify:
- Prescribed a CFTR modulator therapy and planning to commence modulator therapy within 30 days OR planning to switch modulator therapies within 30 days
- Participates in the Canadian Cystic Fibrosis Registry (CCFR)
- willing to sign a consent form by participant, or parent/legal guardian or assent
Who Should NOT Join This Trial:
- Known contraindications to CFTR modulator therapy
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Prescribed a CFTR modulator therapy and planning to commence modulator therapy within 30 days OR planning to switch modulator therapies within 30 days
* Participates in the Canadian Cystic Fibrosis Registry (CCFR)
* Informed consent by participant, or parent/legal guardian or assent
Exclusion Criteria:
* Known contraindications to CFTR modulator therapy
Treatments Being Tested
DRUG
Trikafta
Highly Effective CFTR Modulator Therapy
Locations (2)
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
St Paul's Hospital
Vancouver, British Columbia, Canada